Lorlatinib NEW
| Price | $93 | $155 | $249 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-23 |
Product Details
| Product Name: Lorlatinib | CAS No.: 1454846-35-5 |
| Purity: 99.95% | Supply Ability: 10g |
| Release date: 2025/05/23 |
Product Introduction
Bioactivity
| Name | Lorlatinib |
| Description | Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. |
| Cell Research | Cells are seeded in 96-well plates in growth medium containing 10% FBS and are cultured overnight at 37°C. The following day, serial dilutions of PF-06463922 or appropriate controls are added to the designated wells, and cells are incubated at 37°C for 72 h. A CellTiter-Glo assay is performed to determine the relative cell numbers. IC50 values are calculated by concentration-response curve fitting using a four-parameter analytical method. |
| Kinase Assay | Recombinant human wild-type and mutant ALK kinase domain proteins (amino acids 1093–1411) are produced in-house using baculoviral expression, preactivated via autophosphorylation with MgATP, and assayed for kinase activity using a microfluidic mobility shift assay. The reactions contained 1.3 nM wild-type ALK or 0.5 nM mutant ALK (appropriate to produce 15-20% phosphorylation of peptide substrate after 1 h of reaction), 3 μM 5-FAM-KKSRGDYMTMQIG-CONH2), 5 mM MgCl2, and the Km level of ATP in 25 mM Hepes, pH 7.1. The inhibitors are shown to be ATP-competitive from kinetic and crystallographic studies. The Ki values are calculated by fitting the conversion (%) to a competitive inhibition equation. ROS1 enzyme is assayed as described above for ALK, except using 0.25 nM recombinant human ROS1 catalytic domain (amino acids 1883-2347). Kinase inhibitor selectivity is evaluated using a 206-kinase panel. |
| In vitro | PF-06463922 effectively inhibits cell proliferation and induces apoptosis in HCC78 human NSCLC cells containing SLC34A2-ROS1 fusions and in BaF3-CD74-ROS1 cells expressing human CD74-ROS1. It also demonstrates this inhibitory action on cell proliferation and induces apoptosis in NSCLC cells with either non-mutated or mutated ALK fusions. PF-06463922 exhibits significant cellular activity against ALK and a wide range of ALK clinical mutations (IC50=0.2-77 nM). |
| In vivo | In NIH3T3 xenograft models expressing human CD74-ROS1 and Fig-ROS1, PF-06463922 inhibits cell proliferation by repressing ROS1 phosphorylation and downstream signaling molecules, including Cyclin D1. Furthermore, PF-06463922 demonstrates significant antitumor activity in mice bearing tumor grafts that overexpress EML4-ALK, EML4-ALK-L1196M, EML4-ALK-G1269A, EML4-ALK-G1202R, or NPM-ALK. |
| Storage | keep away from moisture,store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 40.6 mg/mL (99.9 mM), Sonication is recommended. DMSO : 15 mg/mL (36.91 mM), Sonication is recommended. |
| Keywords | TyrosineKinases | Tyrosine Kinases | tyrosine | third-generation | ROSKinase | ROS1 | ROS Kinase | ROS | PF6463922 | PF06463922 | PF 6463922 | PF 06463922 | NSCLC | Neuroblastoma | mutation | LTK (TYK1) | Lorlatinib | kinase | Inhibitor | inhibit | Cluster of differentiation 246 | CD246 | Carcinoma | brain-penetrant | Apoptosis | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK (L1196M) | ALK |
| Inhibitors Related | Stavudine | Allopurinol | Cysteamine hydrochloride | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | Inosine | L-Ascorbic acid sodium salt | Alginic acid | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2025-05-26 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2025-01-09 | |
| $8.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-03-29 | |
| $0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2023-12-29 | ||
| $20.00/10g |
Hebei Brisk New Material Technology Co. , Ltd.
|
2023-05-31 | ||
| $200.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-11-28 | ||
| $50.00/1KG |
Qiuxian Baitai New Material Co., LTD
|
2021-11-04 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $100.00/1ASSAYS |
Handan Tongyi New Material Technology Co., Ltd
|
2021-03-08 | ||
| $1.00/1BOU/Drum |
HONG KONG IPURE BIOLOGY CO.,LIMITED
|
2020-11-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY